Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Congrong Yizhi is a traditional Chinese medicine compound formulation used primarily for the treatment of cognitive impairment and vascular dementia. It is available as capsules and contains multiple herbal ingredients including Cistanches Herba (Cistanche deserticola), Polygoni Multiflori Radix Praeparata (processed Polygonum multiflorum root), Folium nelumbinis (lotus leaf), Pheretima (earthworm extract), and Rhapontici Radix. The mechanism of action is believed to involve neuroprotection, improvement of cerebral blood flow, anti-inflammatory effects, and reduction of β-amyloid-induced neuronal damage. Preclinical studies suggest it may reduce MARCKS mRNA levels in the hippocampus in dementia models[6]. It has been licensed for mild to moderate vascular dementia with symptoms such as stasis obstructing brain collaterals and blood stasis-phlegm[5]. Adverse effects can include drug-induced liver injury[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fufang congrong yizhi.